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In 2015, globally over 236 million individuals aged 25 years
had peripheral artery disease (PAD), a serious health condition
with a high morbidity burden and mortality risk [1]. PAD
shares several risk factors with chronic kidney disease (CKD),
including smoking, diabetes, hypertension and hypercholester-
olaemia. Moreover, patients with established PAD are at in-
creased risk of other vascular events including CKD, ischaemic
heart disease, heart failure and stroke [2]. Correction of estab-
lished cardiovascular risk factors may reduce the risk of PAD
and its complications, but additional therapeutic targets need to
be identified in order to improve outcomes in this high-risk
population. Among these targets are non-traditional cardiovas-
cular risk factors, which can be targeted with pharmacological
or non-pharmacological interventions.
Several mechanisms may be involved in the aetiology of
PAD. Intimal atherosclerosis and plaque formation, driven by
traditional cardiovascular risk factors, are common and play a
prominent role in PAD development. In addition, calcification
of the tunica media, which is highly prevalent in patients with
advanced CKD and diabetes, can promote PAD [3]. Over the
past years, several studies have highlighted a role for magne-
sium as a direct modulator of vascular (media) calcification,
among others through effects on pro-osteogenic signalling and
hydroxyapatite formation (Figure 1). Interestingly, magnesium
can also influence atherosclerosis, among others through im-
proving endothelial function by reducing inflammation and
altering lipid metabolism [4, 5]. Epidemiological studies have
shown inverse correlations of serum magnesium levels and
cardiovascular morbidity and mortality in CKD patients [6].
Recently, two studies addressed whether serum magnesium
is associated with the risk of developing PAD in the general
population [7, 8]. Both studies used data from the
Atherosclerosis Risk in Communities (ARIC) cohort, a large
prospective study conducted in four US communities. Sun et al.
[7] studied 13 826 ARIC participants aged 40–64 years, and
found that a lower serum magnesium level was independently
associated with an increased risk of developing PAD during a
median follow-up of 24.4 years. Individuals in the lowest serum
magnesium quintile (1.4 mEq/L) had a 30% higher risk of
developing PAD, compared with those in the highest magne-
sium quintile (1.8 mEq/L, P< 0.001), after adjustment for
several potential confounders. The shape of this association was
nonlinear (J-shaped), with individuals in the lower range being
at increased risk, while a higher magnesium level did not seem
to provide additional protection compared with the group me-
dian. In patients with mild to moderate CKD, serum magne-
sium may be normal or low, the latter particularly due to
treatment with proton-pump inhibitors, thiazide diuretics and
other drugs [9].
In this issue of Nephrology Dialysis Transplantation, Menez
et al. [8] extended the initial results from the ARIC cohort by
focusing on the interaction by estimated glomerular filtration
rate (eGFR). In individuals with an eGFR >60 mL/min/1.73 m2
(n¼ 11 606 of whom 436 developed PAD), there was a strong
and consistent inverse association between serum magnesium
and PAD risk. In contrast, this association was not present in
participants with an eGFR <60 mL/min/1.73 m2, who seemed
to have a similar distribution of magnesium levels compared
with individuals with an eGFR>60 mL/min/1.73 m2. It is, how-
ever, important to note that the analyses in the low eGFR group
had considerably less statistical power, since this subgroup con-
sisted of only 233 ARIC participants, 35 of whom developed
PAD. In particular, the further adjusted Cox regression models
that contained more than 10 covariates are prone to overfitting,
potentially blunting the results. Unfortunately, results from crude
or minimally adjusted analyses in this subgroup were not pro-
vided. Alternatively, using a higher eGFR cut-off (e.g. 70 mL/
min/1.73 m2) may allow to increase the sample size to get a more
robust impression of the association between serum magnesium
and incident PAD in individuals with (mildly) impaired kidney
function. Yet, the observation by Menez et al. might indicate that
a low magnesium level is a less important risk factor for PAD in
CKD patients. Possibly, other factors such as deregulated mineral
metabolism (hyperparathyroidism tended to be associated with a
higher PAD risk in patients with an eGFR<60 mL/min/1.73 m2)
or hyperphosphataemia may be more important risk factors than
low magnesium levels in this population, especially in CKD Stage
G5 where hypermagnesaemia develops frequently [10].
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How can this observation be reconciled with emerging data
that seem to position magnesium as an important factor in the
prevention of vascular calcification in CKD? A substantial body
of in vitro and in vivo studies has demonstrated that vascular
calcification is significantly delayed under high magnesium
conditions [6]. Multiple molecular mechanisms may contribute
to the development of vascular calcification, including extracel-
lular formation of calcium-containing particles and transdiffer-
entiation of vascular smooth muscle cells in osteoblast-like cells
[6, 11]. Magnesium has been proposed to interfere with this
transdifferentiation process at several levels: (i) it may function
as calcium channel antagonist and thereby reduces cellular cal-
cium uptake; (ii) magnesium uptake via transient receptor po-
tential melastatin type 7 channels may directly inhibit pro-
osteogenic gene transcription; and (iii) magnesium activates the
calcium-sensing receptor and thereby inhibits calcification [11].
However, recent data from our groups indicate that in
particular the circulating calcium- and phosphate-containing
particles may play an essential role. In CKD, high serum phos-
phate levels promote the formation of the so-called secondary
calciprotein particles (CPPs). Secondary CPPs contain crystal-
line calcium–phosphate and are considered an important driver
of CKD-associated vascular calcification. Recent in vitro studies
indicated that magnesium can inhibit the formation of
phosphate-induced secondary CPPs, preventing calcification of
vascular smooth muscle cells [12]. However, once secondary
CPPs had been formed, magnesium supplementation did not
halt vascular smooth muscle cells calcification [12]. These find-
ings suggest that magnesium supplementation may be of partic-
ular interest in early stages of CKD, when secondary CPP
formation and calcium deposits in the vessel wall are not yet
present. The observation by Menez et al. that the association be-
tween magnesium and PAD is weaker in patients with an eGFR
<60 mL/min/1.73 m2 is in line with this hypothesis. Large
epidemiological studies and clinical trials would be required to
address the hypothesis that patients with early stages of CKD
particularly benefit from magnesium supplementation.
Interestingly, Menez et al. show the lowest hazard risk of inci-
dent PAD in patients with serum magnesium levels >1.8 mEq/L,
which is near the upper limit of the normal range (1.4–2.0
mEq/L). Patients who were well within the population-based
reference interval already had an increased risk of PAD. Similar
observations were reported in the Renal Data Registry of the
Japanese Society for Dialysis Therapy and in the CONvective
TRAnsport STudy (CONTRAST) [13, 14]. These findings suggest
that the clinically optimal range is higher than previously assumed
and higher than the serum magnesium level that is currently
strived for in the clinic.
While it seems that the jury is still out regarding the role of
low serum magnesium levels and the risk of PAD in individuals
with impaired kidney function, the overall results from the
ARIC study set the stage for clinical trials that further explore
magnesium as a target for intervention. In fact, several preclini-
cal and clinical studies have confirmed that higher dietary
magnesium intake reduces vascular stiffness and calcification.
In klotho knockout mice, an animal model that actually reflects
many aspects of the CKD phenotype, high magnesium intake
prevented vascular calcification [15]. Similar results were
obtained in uraemic rats and other genetic mouse models of cal-
cification [16–18]. In humans, magnesium supplementation re-
duced vascular stiffness in overweight healthy individuals [19].
In a currently on-going clinical trial, we aim to further refine
these results by addressing whether the anion that accompanies
magnesium influences the association with vascular stiffness
[20]. Randomized controlled trials in CKD patients demon-
strated that both oral and dialysate magnesium supplementa-
tion improved calcification propensity [21, 22]. Moreover,
















FIGURE 1: Schematic overview of potential mechanisms by which magnesium (Mg2þ) protects against PAD. On one hand, Mg2þ may reduce
medial calcification (right side), by inhibiting the conversion of primary CPPs to secondary CPPs, promoting hydroxyapatite crystal deposition
in the tunica media. In addition, Mg2þ may inhibit vascular smooth muscle cell transdifferentiation in the media layer. On the other hand,
Mg2þ may also influence low-density lipoprotein cholesterol metabolism and reduce inflammation in the tunica intima, which may retard ath-
erosclerotic plaque development (left side). HA, hydroxyapatite; LDL, low-density lipoprotein; pCPP, primary CPP; sCPP, secondary CPP;
VSMC, vascular smooth muscle cell.
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calcification in CKD patients [23], demonstrating the efficacy
of magnesium on a clinically relevant endpoint.
Insufficient magnesium intake is abundant throughout the
population [24], and a considerable proportion of the CKD and
kidney transplant populations use drugs that influence magne-
sium uptake and metabolism, including proton-pump inhibi-
tors and calcineurin inhibitors [25, 26]. Consequently, it
remains timely and relevant to address whether magnesium de-
ficiency plays a major role in the alarmingly high rates of car-
diovascular complications. At the same time, side effects of high
magnesium intake, including gastrointestinal complaints and
potential disturbances of bone metabolism, should be moni-
tored. Despite the large sample size and the long-term follow-
up of the ARIC cohort, more CKD-specific data are needed to
reach a final verdict on low serum magnesium as a risk factor
for PAD and other cardiovascular outcomes in these patients.
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